[go: up one dir, main page]

EA202092065A1 - ЭКСПРЕССИЯ ПНЕВМОКОККОВОГО ПОВЕРХНОСТНОГО БЕЛКА А (PspA) - Google Patents

ЭКСПРЕССИЯ ПНЕВМОКОККОВОГО ПОВЕРХНОСТНОГО БЕЛКА А (PspA)

Info

Publication number
EA202092065A1
EA202092065A1 EA202092065A EA202092065A EA202092065A1 EA 202092065 A1 EA202092065 A1 EA 202092065A1 EA 202092065 A EA202092065 A EA 202092065A EA 202092065 A EA202092065 A EA 202092065A EA 202092065 A1 EA202092065 A1 EA 202092065A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pspa
expression
surface protein
pneumococcal surface
discloses
Prior art date
Application number
EA202092065A
Other languages
English (en)
Inventor
Раджан Срираман
Рамеш Венкат Матур
Нарендер Дев Мантена
Махима Датла
Светха Камиредди
Original Assignee
Байолоджикал И Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байолоджикал И Лимитед filed Critical Байолоджикал И Лимитед
Publication of EA202092065A1 publication Critical patent/EA202092065A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/77—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Corynebacterium; for Brevibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Настоящее изобретение относится к экспрессии пневмококкового поверхностного белка A (PspA). Изобретение представляет собой усовершенствование в области генной инженерии и технологии вакцин. В изобретении раскрыты экспрессионные векторы и рекомбинантные клетки-хозяева для экспрессии усеченного пептида PspA. В изобретении также раскрыты вакцинные композиции, содержащие усеченные пептиды в качестве белка-носителя.
EA202092065A 2018-03-01 2019-03-01 ЭКСПРЕССИЯ ПНЕВМОКОККОВОГО ПОВЕРХНОСТНОГО БЕЛКА А (PspA) EA202092065A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201841007814 2018-03-01
PCT/IB2019/051655 WO2019167008A1 (en) 2018-03-01 2019-03-01 Expression of pneumococcal surface protein a (pspa)

Publications (1)

Publication Number Publication Date
EA202092065A1 true EA202092065A1 (ru) 2020-11-19

Family

ID=66440079

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092065A EA202092065A1 (ru) 2018-03-01 2019-03-01 ЭКСПРЕССИЯ ПНЕВМОКОККОВОГО ПОВЕРХНОСТНОГО БЕЛКА А (PspA)

Country Status (19)

Country Link
US (2) US11725029B2 (ru)
EP (1) EP3758746A1 (ru)
JP (2) JP7334176B2 (ru)
KR (1) KR102774793B1 (ru)
CN (1) CN112118865B (ru)
AU (1) AU2019226487A1 (ru)
BR (1) BR112020017431A2 (ru)
CA (1) CA3091583A1 (ru)
CL (1) CL2020002246A1 (ru)
CU (1) CU24709B1 (ru)
EA (1) EA202092065A1 (ru)
IL (1) IL277023B1 (ru)
MX (1) MX2020009049A (ru)
PH (1) PH12020551357A1 (ru)
SA (1) SA520420041B1 (ru)
SG (1) SG11202008124XA (ru)
UA (1) UA129585C2 (ru)
WO (1) WO2019167008A1 (ru)
ZA (1) ZA202005414B (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
JP2024533373A (ja) 2021-09-09 2024-09-12 アフィニバックス、インコーポレイテッド 多価肺炎球菌ワクチン

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476929A (en) * 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
ES2444785T3 (es) * 2004-09-09 2014-02-26 Research Institute Of Innovative Technology For The Earth Fragmento de ADN que tiene función promotora
EP3020811A1 (en) 2008-06-25 2016-05-18 Vaxiion Therapeutics, LLC Regulated genetic suicide mechanism compositions and methods
WO2010141312A2 (en) 2009-06-01 2010-12-09 Wake Forest University Health Sciences Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
GB201003924D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
CN107674118A (zh) * 2016-08-02 2018-02-09 中国食品药品检定研究院 重组蛋白PspA1、PspA2和PspA3以及包含其的多糖结合疫苗

Also Published As

Publication number Publication date
PH12020551357A1 (en) 2021-08-23
US20230322871A1 (en) 2023-10-12
CN112118865A (zh) 2020-12-22
CA3091583A1 (en) 2019-09-06
CU24709B1 (es) 2024-06-11
IL277023B1 (en) 2025-07-01
CN112118865B (zh) 2025-03-28
IL277023A (en) 2020-10-29
MX2020009049A (es) 2020-10-12
JP2023154063A (ja) 2023-10-18
JP7645946B2 (ja) 2025-03-14
KR20200129121A (ko) 2020-11-17
SA520420041B1 (ar) 2024-03-14
JP2021516050A (ja) 2021-07-01
KR102774793B1 (ko) 2025-02-27
US11725029B2 (en) 2023-08-15
AU2019226487A1 (en) 2020-09-10
ZA202005414B (en) 2022-02-23
UA129585C2 (uk) 2025-06-11
US20210009641A1 (en) 2021-01-14
EP3758746A1 (en) 2021-01-06
JP7334176B2 (ja) 2023-08-28
CU20200064A7 (es) 2021-04-07
SG11202008124XA (en) 2020-09-29
CL2020002246A1 (es) 2021-01-15
WO2019167008A1 (en) 2019-09-06
BR112020017431A2 (pt) 2021-01-19

Similar Documents

Publication Publication Date Title
EA202190906A1 (ru) Рекомбинантное получение препаратов пептидов коллагена и их применение
BR112021018776A2 (pt) Vetores de vírus adenoassociado recombinante
EA201991911A1 (ru) Способы и композиции для переноса генов по сосудистой сети
UA120917C2 (uk) Химерний білок фактора viii та його застосування
MX2018010824A (es) Proteinas de union inducibles y metodos de uso.
MX2020010466A (es) Vectores de virus que evitan anticuerpos.
EA201892561A1 (ru) Гибридные белки gdf15 и их применение
MX2020010464A (es) Vectores de virus que evitan anticuerpos.
UA124343C2 (uk) Капсиди аденоасоційованого вірусу і спосіб його використання
EA201890640A1 (ru) Рекомбинантные векторы, содержащие пептид 2а
MX2017004664A (es) Conjugados de farmacos de anticuerpos modificados mediante glicoingenieria.
AR091735A1 (es) Complejo de factor viii con xten y proteina factor de von willebrand (vwf) y usos del mismo
EA201391331A1 (ru) Активные и селективные ингибиторы nav1.3 и nav1.7
MX2018000697A (es) Peptidos anti-inflamatorios y usos de los mismos.
EA201991409A2 (ru) Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
CL2017000200A1 (es) Célula huésped mejorada para producir proteinas
EA202091352A1 (ru) Генотерапия мукополисахаридоза iiib
MX2022013963A (es) Composiciones de virus adenoasociados compatibles entre especies y metodos de uso de las mismas.
EP2589658A4 (en) PARTIAL REGION POLYPEPTIDE OF REIC / DKK-3 PROTEIN
EA202092065A1 (ru) ЭКСПРЕССИЯ ПНЕВМОКОККОВОГО ПОВЕРХНОСТНОГО БЕЛКА А (PspA)
MX390966B (es) Vacunas contra el dengue
CO2017011431A2 (es) Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina
EA201890274A1 (ru) Векторная система из аденовируса 9 птиц (fadv-9) и связанные способы
ZA202308985B (en) Constructs and methods for increased expression of polypeptides
CO2022004535A2 (es) Secuencia de extensión n-terminal para la expresión de péptidos terapéuticos recombinantes